Lublin F, Miller DH, Freedman MS, et al. Oral fingolimod in primary progressive multiple sclerosis (INFORMS): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet 2016; 387: 1075–84—In this Article, the list of principal investigators in the appendix has been updated. This correction has been made to the online version as of Jan 19, 2017.
from #AlexandrosSfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/2jEPv6S
via IFTTT
Εγγραφή σε:
Σχόλια ανάρτησης (Atom)
Δημοφιλείς αναρτήσεις
-
Cancer is associated with genomic instability and aging. Genomic instability stimulates tumorigenesis, whereas deregulation of oncogenes acc...
-
Caring for Patients with Physical Disabilities: Assessment of an Innovative Spinal Cord Injury Session that Addresses an Educational Gap Des...
-
<span class="paragraphSection"><div class="boxTitle">Abstract</div>It is not clear whether breast canc...
-
Related Articles Disrupted relationship between "resting state" connectivity and task-evoked activity during social percepti...
-
Abstract Helmet manufacturers recommend replacing a bicycle helmet after an impact or after anywhere from 2 to 10 years of use. The goal o...
-
Objectives Adult sagittal posture is established during childhood and adolescence. A flattened or hypercurved spine is associated with poore...
-
Summary Emergency cricothyrotomy is a common feature in all difficult airway algorithms. It is the final step following a ‘can't intub...
-
Publication date: 10 June 2017 Source: Journal of Controlled Release, Volume 255 Author(s): Ožbej Zupančič, Andreas Bernkop-Schnürch Pept...
-
Ocular Vestibular Evoked Myogenic Potentials: Where Are We Now? Objective: Over the last decade, ocular vestibular evoked myogenic potential...
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου